title: Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.
abstract: OBJECTIVE
  It is unclear whether hepatitis C virus (HCV) is eradicated in patients with chronic hepatitis C who achieved a sustained virologic response (SVR).
  
  
  METHODS
  In this long-term follow-up study, including chronic hepatitis C patients who achieved SVR after interferon-based therapy, the presence of residual HCV RNA in serum, liver, and peripheral blood mononuclear cells (PBMCs) was assessed, using transcription-mediated amplification (sensitivity, <9.6 IU/mL). The benefit of SVR on liver fibrosis was evaluated using the METAVIR score.
  
  
  RESULTS
  A total of 344 patients were followed up for a median duration of 3.27 years (range, 0.50-18 y; interquartile range [IQR], 1.68-5.35 y). A total of 114 patients had a posttreatment liver tissue (median, 0.50 y; range, 0-14 y; IQR, 0-3.5 y) and a total of 156 had one PBMC (median, 3.0 y; range, 0.50-18 y; IQR, 1.25-5.50 y). Serum HCV RNA remained undetectable (1300 samples), indicating that none of the patients had a relapse. HCV RNA was detectable in 2 of 114 (1.7%) liver specimens, and in none of 156 PBMC specimens. Histologic analysis of 126 paired pretreatment and posttreatment liver biopsy specimens (median, 0.50 y; range, 0-14 y; IQR, 0-3.5 y) showed that fibrosis stage was improved in 56%, stable in 32%, deteriorated in 12%. Regression of cirrhosis was observed in 9 of 14 (64%) (95% confidence interval, 39-89) patients. No cirrhosis decompensation was observed, and 3 patients developed hepatocellular carcinoma.
  
  
  CONCLUSIONS
  In this large cohort of chronic hepatitis C patients, SVR was durable up to 18 years after treatment cessation, in addition to fibrosis stability/improvement (88%) and cirrhosis regression (64%). The presence of residual HCV RNA was observed only in liver tissue (1.7%). This result strongly suggests that SVR may be considered to show eradication of HCV infection.
authors.affiliation: Université Paris VII, Hôpital Beaujon, Clichy, France.
authors.forename: Sarah
authors.initials: S
authors.lastname: Maylin
authors.forename: Michelle
authors.initials: M
authors.lastname: Martinot-Peignoux
authors.forename: Rami
authors.initials: R
authors.lastname: Moucari
authors.forename: Nathalie
authors.initials: N
authors.lastname: Boyer
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Ripault
authors.forename: Dominique
authors.initials: D
authors.lastname: Cazals-Hatem
authors.forename: Nathalie
authors.initials: N
authors.lastname: Giuily
authors.forename: Corinne
authors.initials: C
authors.lastname: Castelnau
authors.forename: Ana Carolina
authors.initials: AC
authors.lastname: Cardoso
authors.forename: Tarik
authors.initials: T
authors.lastname: Asselah
authors.forename: Cyrille
authors.initials: C
authors.lastname: Féray
authors.forename: Marie Hélène
authors.initials: MH
authors.lastname: Nicolas-Chanoine
authors.forename: Pierre
authors.initials: P
authors.lastname: Bedossa
authors.forename: Patrick
authors.initials: P
authors.lastname: Marcellin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use; D004279:DNA, Viral / Q000097:blood; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D007372:Interferons; D000410:Alanine Transaminase